文献速递前列腺癌

18F-PSMA-11与68Ga-PSMA-11正电子发射断层扫描/计算机断层扫描用于前列腺癌分期与生化复发的前瞻性双盲随机交叉试验

18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
PubMed 文献 · Eur Urol · 2022-06-08

前瞻性双盲随机交叉试验纳入82例前列腺癌患者(原发或生化复发),每例均接受18F-PSMA-11与68Ga-PSMA-11 PET/CT。主要终点达成:18F-PSMA-11在阳性扫描数上不劣于68Ga-PSMA-11;仅在参考阅片者的miPSMA表达评分上显示优势。

要点

  • 18F-PSMA-11在阳性扫描比例上不劣于68Ga-PSMA-11。
  • 仅参考阅片者的miPSMA表达评分显示18F-PSMA-11更高。
  • 两种示踪剂的阅片者间一致性为公平至良好且相等。

核心结论

  • 示踪剂18F-PSMA-11不劣于68Ga-PSMA-11。
  • 18F-PSMA-11的优势仅限于参考阅片者给出的miPSMA表达评分。
  • 阅片者间一致性为公平至良好,且两种放射性示踪剂相等。

研究设计与样本

  • 前瞻性、双盲、随机交叉试验,每例患者均接受18F-PSMA-11和68Ga-PSMA-11 PET/CT。
  • 纳入原发或生化复发的前列腺癌患者,共82例纳入扫描分析。
  • 所有扫描由三名独立经验丰富的核医学医师按照Eiber等提出的PSMA配体PET/CT判读指南进行审阅和评分。

主要发现

  • 主要终点达成:三名阅片者评定的每例患者阳性扫描比例,18F-PSMA-11/68Ga-PSMA-11分别为67%/67%、65%/65%和73%/70%。
  • 参考阅片者的miPSMA表达评分18F-PSMA-11高于68Ga-PSMA-11。
  • 随访数据显示18F-PSMA-11与68Ga-PSMA-11扫描的估计敏感性相同(三名阅片者分别为0.92、0.83和0.92)。
  • 患者水平阅片者间一致性为公平至良好,两种示踪剂的Light's kappa值均为0.59。

临床怎么用

  • 18F-PSMA-11可作为68Ga-PSMA-11的替代用于检测前列腺癌。
  • 作者认为该示踪剂的可能优势应在特定亚群中进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fluorine-18 (18F)-labelled prostate-specific membrane antigen (PSMA) offers several advantages over gallium-68 (68Ga) in terms of costs, yield, transport/distribution, and image resolution. OBJECTIVE: This trial investigates the new radiotracer 18F-PSMA-11 via a prospective, intraindividual crossover design. The trial was powered for noninferiority of 18F-PSMA-11 over 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in terms of the number of positive PET scans. Secondary endpoints were as follows: (1) superiority of 18F-PSMA-11 over 68Ga-PSMA-11 with respect to the number of positive PET scans, the total number of suspicious prostate cancer lesions, and the miPSMA expression score of corresponding lesions; (2) correlation of the PET/CT images with available follow-up data for 18F-PSMA-11 and 68Ga-PSMA-11; and (3) assessment of the interobserver variability. DESIGN, SETTING, AND PARTICIPANTS: Prostate cancer patients (primary or biochemical recurrence) were randomised in a double-blind crossover design whereby each patient received both 18F-PSMA-11 and 68Ga-PSMA-11 PET/CT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All scans were reviewed and scored by three independent experienced nuclear physicians following the proposed guideline for the interpretation of PSMA-ligand PET/CT, as described by Eiber et al. RESULTS AND LIMITATIONS: In total, 82 patients were included for scan analyses. The primary endpoint was met: per patient, the proportions of positive scans rated by the three readers were 67%/67%, 65%/65%, and 73%/70% for 18F-PSMA-11/68Ga-PSMA-11 PET/CT. The miPSMA expression score was higher for 18F-PSMA-11 than for 68Ga-PSMA-11 for the reference reader. Follow-up data showed identical estimated sensitivity for both the 18F-PSMA-11 and the 68Ga-PSMA-11 scan (0.92, 0.83, and 0.92 for the three readers). A fair to good agreement among readers (at patient level) was obtained, which was demonstrated by a Light's kappa value of 0.59 for both tracers. CONCLUSIONS: The tracer 18F-PSMA-11 is noninferior to68Ga-PSMA-11. Superiority of 18F-PSMA-11 was limited to the miPSMA expression score, given by the reference reader. Inter-rater agreement was fair to good, and equal for both radiotracers. PATIENT SUMMARY: In this study, we compared two radiotracers: 18F-PSMA-11 and 68Ga-PSMA-11. We proved that 18F-PSMA-11 is not inferior to 68Ga-PSMA-11 for detecting prostate cancer and thus can be used as an alternative. Possible superiority of this tracer should be further investigated in specific subpopulations.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. De Man K, Van Laeken N, Schelfhout V, et al. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. Eur Urol. 2022. PMID: 35690515. doi:10.1016/j.eururo.2022.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。